In conclusion, our study suggests that pretreatment serum cytokine levels could predict the clinical efficacy as well as PFS in patients with NSCLC undergoing anti-PD-1 blockade therapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.